FDA Panel Backs Peptides, Legal Access Still Uncertain

FDA panel backed seven peptides despite safety concerns, but availability remains uncertain. Compounding pharmacies may gain approval via Category One list, though timelines vary. Demand outpaces evidence, and prescriptions would require pharmacies to prepare them.